Mettler-Toledo International (NYSE:MTD) Upgraded by Citigroup to Buy Rating

Citigroup upgraded shares of Mettler-Toledo International (NYSE:MTD) from a neutral rating to a buy rating in a report issued on Monday morning, MarketBeat.com reports. The brokerage currently has $1,400.00 target price on the medical instruments supplier’s stock.

Several other research analysts also recently commented on MTD. Wells Fargo & Company lifted their price target on shares of Mettler-Toledo International from $1,350.00 to $1,400.00 and gave the stock an “equal weight” rating in a research note on Monday, February 10th. Evercore ISI boosted their price target on shares of Mettler-Toledo International from $1,450.00 to $1,475.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. Robert W. Baird upped their price target on shares of Mettler-Toledo International from $1,362.00 to $1,369.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Finally, Wolfe Research assumed coverage on Mettler-Toledo International in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Mettler-Toledo International has a consensus rating of “Hold” and a consensus target price of $1,380.50.

Mettler-Toledo International Stock Performance

NYSE MTD opened at $1,033.42 on Monday. The company has a market capitalization of $21.54 billion, a P/E ratio of 25.50, a P/E/G ratio of 3.30 and a beta of 1.28. Mettler-Toledo International has a 52-week low of $961.83 and a 52-week high of $1,546.93. The company has a fifty day moving average of $1,257.88 and a 200-day moving average of $1,290.80.

Mettler-Toledo International (NYSE:MTD) last posted its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $12.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.76 by $0.65. Mettler-Toledo International had a negative return on equity of 591.54% and a net margin of 22.29%. As a group, analysts forecast that Mettler-Toledo International will post 42.71 EPS for the current fiscal year.

Insider Activity

In other Mettler-Toledo International news, insider Gerry Keller sold 600 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1,351.34, for a total transaction of $810,804.00. Following the transaction, the insider now directly owns 6 shares of the company’s stock, valued at approximately $8,108.04. The trade was a 99.01 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christian Magloth sold 790 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $1,313.69, for a total transaction of $1,037,815.10. Following the completion of the transaction, the insider now owns 734 shares of the company’s stock, valued at $964,248.46. This trade represents a 51.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.94% of the company’s stock.

Hedge Funds Weigh In On Mettler-Toledo International

Several hedge funds and other institutional investors have recently modified their holdings of MTD. Alliancebernstein L.P. boosted its position in Mettler-Toledo International by 9.9% during the 4th quarter. Alliancebernstein L.P. now owns 583,181 shares of the medical instruments supplier’s stock valued at $713,627,000 after acquiring an additional 52,726 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Mettler-Toledo International by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 558,471 shares of the medical instruments supplier’s stock valued at $682,340,000 after purchasing an additional 11,032 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Mettler-Toledo International by 6.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,739 shares of the medical instruments supplier’s stock valued at $557,680,000 after purchasing an additional 25,873 shares during the period. GAMMA Investing LLC boosted its position in shares of Mettler-Toledo International by 131,246.3% during the first quarter. GAMMA Investing LLC now owns 386,158 shares of the medical instruments supplier’s stock valued at $456,018,000 after purchasing an additional 385,864 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its stake in Mettler-Toledo International by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 363,107 shares of the medical instruments supplier’s stock worth $444,327,000 after purchasing an additional 96,300 shares during the period. Hedge funds and other institutional investors own 95.07% of the company’s stock.

About Mettler-Toledo International

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company’s laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments.